NCT00991419View on ClinicalTrials.gov

To Compare Positron Emission Tomography (PET) Measurements of Fibrillar Amyloid Burden

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

August 31, 2011

Study Completion Date

August 31, 2011

Conditions
Alzheimer's Disease
Interventions
DRUG

[18F]AZD4694

\[18F\]AZD4694 PET Ligand administered at Visit 1, 30 days following screening and at visit 4 for some of the participants.

Trial Locations (1)

Unknown

Research Site, Phoenix

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY